Drive Wealth Management LLC purchased a new position in BioVie Inc. (NASDAQ:BIVI – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 60,000 shares of the company’s stock, valued at approximately $120,000. Drive Wealth Management LLC owned 0.34% of BioVie at the end of the most recent reporting period.
Separately, Sanders Morris Harris LLC bought a new position in BioVie in the 4th quarter worth approximately $85,000. Institutional investors own 4.59% of the company’s stock.
BioVie Stock Performance
NASDAQ BIVI opened at $1.81 on Wednesday. The company has a market capitalization of $32.16 million, a P/E ratio of -0.16 and a beta of 0.49. BioVie Inc. has a one year low of $1.04 and a one year high of $33.10. The stock has a 50 day moving average price of $2.44 and a 200-day moving average price of $2.19.
BioVie Company Profile
BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
Recommended Stories
- Five stocks we like better than BioVie
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What Are Earnings Reports?
- What Does the Future Hold for Eli Lilly?
- How Can Investors Benefit From After-Hours Trading
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.